Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

About this update from Coherus Oncology, Inc.

[{"type":"image","alt":"Coherus Oncology, Inc.","displaySize":"","headline":null,"caption":"Coherus Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/de46623a0f67971b50edcbf1ccfac170"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Oe14ACN4sd6wayCRQj8VlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/de46623a0f67971b50edcbf1ccfac170","width":300,"height":90}},"lazy":false},{"type":"text","content":"-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy -","length":190,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The findings reveal a striking and durable survival advantage that underscores the urgent clinical need to incorporate LOQTORZI with chemotherapy as first-line treatment.","length":494,"tagName":"p"},{"type":"text","content":"In this exploratory post-hoc analysis, patients receiving LOQTORZI plus gemcitabine and cisplatin achieved a median OS of 64.8 months, nearly double that of chemotherapy alone (33.7 months), representing a 31-month improvement and an observed 38% reduction in risk of death (HR 0.62; 95% CI, 0.45–0.85). These results, presented at ESMO Asia 2025, signal a step change in cancer patient survival, reinforcing LOQTORZI’s role in transforming outcomes for people living with RM-NPC.","length":485,"tagName":"p"},{"type":"text","content":"JUPITER-02 is a randomized, double-blind, placebo-controlled Phase 3 study evaluating LOQTORZI with chemotherapy in first-line RM-NPC, and this long-term follow-up provides additional context for the previously reported survival outcomes.","length":238,"tagName":"p"},{"type":"text","content":"A Meaningful Shift for Patients Who Need It Most","length":48,"tagName":"p"},{"type":"text","content":"RM-NPC is an aggressive cancer, and long-term survival with standard chemotherapy can be limited for m...

More updates from Coherus Oncology, Inc.